Titan Pharmaceuticals, Inc. (TTNP) Analysts See $-0.15 EPS, Tandem Diabetes Care (TNDM) Sentiment Is 0.8

Analysts expect Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) to report $-0.15 EPS on May, 9.They anticipate $0.06 EPS change or 66.67% from last quarter’s $-0.09 EPS. After having $-0.15 EPS previously, Titan Pharmaceuticals, Inc.’s analysts see 0.00% EPS growth. About 1,750 shares traded. Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) has declined 50.34% since September 27, 2016 and is downtrending. It has underperformed by 60.91% the S&P500.

Tandem Diabetes Care, Inc. is a medical device company. The company has market cap of $47.28 million. The Firm is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. It currently has negative earnings. The Firm makes and sells three insulin pump products, which include t:slim Insulin Delivery System , t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Titan Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company has market cap of $60.95 million. The Firm is engaged in developing therapeutics for the treatment of medical disorders. It has a 13.08 P/E ratio. The Company’s segment is engaged in the development of pharmaceutical products.

Investors sentiment decreased to 0 in Q4 2016. Its down Infinity, from Infinity in 2016Q3. It fall, as 0 investors sold Titan Pharmaceuticals, Inc. shares while 1 reduced holdings. 0 funds opened positions while 0 raised stakes. 38,345 shares or 70.09% less from 128,202 shares in 2016Q3 were reported. Gagnon Limited Liability holds 36,072 shares. Vantage Investment Advisors Lc holds 2,273 shares or 0% of its portfolio.

About 39,813 shares traded. Tandem Diabetes Care Inc (NASDAQ:TNDM) has declined 88.96% since September 27, 2016 and is downtrending. It has underperformed by 99.53% the S&P500.

Dafna Capital Management Llc holds 1.37% of its portfolio in Tandem Diabetes Care Inc for 724,286 shares. Shaker Investments Llc Oh owns 157,940 shares or 0.27% of their US portfolio. Moreover, Iguana Healthcare Management Llc has 0.1% invested in the company for 75,000 shares. The Sweden-based Rhenman & Partners Asset Management Ab has invested 0.1% in the stock. Rock Springs Capital Management Lp, a Maryland-based fund reported 595,000 shares.

Ratings analysis reveals 33% of Tandem Diabetes Care’s analysts are positive. Out of 9 Wall Street analysts rating Tandem Diabetes Care, 3 give it “Buy”, 1 “Sell” rating, while 5 recommend “Hold”. The lowest target is $3.50 while the high is $19.0. The stock’s average target of $10.30 is 984.21% above today’s ($0.95) share price. TNDM was included in 17 notes of analysts from August 5, 2015. On Thursday, November 3 the stock rating was downgraded by PiperJaffray to “Neutral”. The stock has “Outperform” rating by Wedbush on Wednesday, November 2. Piper Jaffray downgraded the stock to “Neutral” rating in Thursday, November 3 report. The firm has “Hold” rating given on Wednesday, November 2 by Stifel Nicolaus. The stock of Tandem Diabetes Care Inc (NASDAQ:TNDM) earned “Buy” rating by Feltl & Co on Wednesday, November 2. Zacks downgraded Tandem Diabetes Care Inc (NASDAQ:TNDM) on Friday, August 28 to “Buy” rating. The firm has “Neutral” rating given on Thursday, January 14 by Bank of America. Robert W. Baird downgraded Tandem Diabetes Care Inc (NASDAQ:TNDM) on Wednesday, November 2 to “Neutral” rating. Zacks upgraded Tandem Diabetes Care Inc (NASDAQ:TNDM) on Saturday, August 22 to “Hold” rating. On Wednesday, August 5 the stock rating was upgraded by Zacks to “Sell”.